AFFiRiS, a Vienna based therapeutic vaccination company, has released results of their phase II study into a therapeutic drug against Alzheimer’s disease.
AFFiRiS said more than 300 people were given doses of proprietary compound AD02 and AD04 with 47% of those given AD04 demonstrating cognitive/functional stabilization or improvement.
Dr Doug Brown, Director of Research and Development at Alzheimer’s Society said having a newly tested drug produce seemingly positive results for people with Alzheimer’s disease was promising, but the full results from this trial were yet to be seen which would give greater indication to the true promise of this potential treatment.
According to AFFiRiS, AD04 could be the first ever drug to demonstrate disease modifying properties in Alzheimer’s patients, with results for the first time meeting all the criteria for disease modifications defined by US and European Regulatory.
The results were dose dependent and more effective in early disease patients.